Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-27
2009-10-27
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S336000, C544S120000, C544S359000, C544S405000, C544S409000, C544S356000, C544S406000, C544S408000, C544S211000, C544S212000, C544S317000, C544S182000, C544S328000, C544S329000, C514S252110, C514S252130, C514S255050, C514S255060, C514S249000, C514S245000, C514S274000, C514S242000, C514S256000
Reexamination Certificate
active
07608618
ABSTRACT:
Compounds of the formulawherein: Y′ is O or S, W′ isoptionally substituted,Z′ is selected from the group consisting ofwherein Q′ is OR7and R7is C1-3alkyleneC3-8heterocycloalkyl useful in the treatment of diseases and conditions related to DNA damage or lesions in DNA replication are disclosed. Methods of making the compounds, and their use as therapeutic agents, for example, in treating cancer and other diseases characterized by defects in DNA replication, chromosome segregation, or cell division also are disclosed.
REFERENCES:
patent: 2762743 (1956-04-01), Basso et al.
patent: 4609659 (1986-09-01), Hartman
patent: 5041653 (1991-08-01), Lee et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 6051218 (2000-04-01), McBride
patent: 6093742 (2000-07-01), Salituro et al.
patent: 6211164 (2001-04-01), Luo et al.
patent: 6218109 (2001-04-01), Elledge et al.
patent: 7067506 (2006-06-01), Keegan et al.
patent: 2132771 (1995-09-01), None
patent: 1 054 004 (2000-11-01), None
patent: 1 096 014 (2001-05-01), None
patent: 1 143 920 (2001-11-01), None
patent: 1 199 306 (2002-04-01), None
patent: 1621447 (1996-02-01), None
patent: 1624949 (1996-02-01), None
patent: WO 93/07128 (1993-04-01), None
patent: WO 94/26715 (1994-11-01), None
patent: WO 96/11930 (1996-04-01), None
patent: WO 99/00357 (1999-01-01), None
patent: WO 99/11621 (1999-03-01), None
patent: WO 99/29674 (1999-06-01), None
patent: WO 99/32433 (1999-07-01), None
patent: WO 99/32436 (1999-07-01), None
patent: WO 99/32463 (1999-07-01), None
patent: WO 00/03005 (2000-01-01), None
patent: WO 00/18738 (2000-04-01), None
patent: WO 00/26203 (2000-05-01), None
patent: WO 00/56725 (2000-09-01), None
patent: WO 00/75120 (2000-12-01), None
patent: WO 01/57034 (2001-08-01), None
Kim, et al., Eur. J. Surg. Oncol., vol. 33, # 5, Jun. 2007, 580-585.
Jin, et al., Genes & Devel. 17:3062-3074, 2003.
Verlinden, et al., Cancer Res. 67, 6574-6581, Jun. 15, 2007.
Tabernero, et al., Ann. Oncol. 2005 16(11):1740-1748.
Sturgeon, et al., Cell Cycle, 2007, vol. 6 # 5, 572-575.
PCT/US1993/03539, Apr. 20, 1993.
S.P. Dutta et al.,J. Carbohydrates Nucleosides Nucleotides, 7(4), 217-240 (1980).
Sanchez et al.,Science, vol. 277, 1497-1501 (1997).
Cecil Textbook of Medicine, 20th edition, vol. 1, pp. 1104-1010 (1996).
Uckun et al., Current Cancer Drug Targets, 1, 59-71 (2001).
PubMed Abstract 14593735, also cited as Prog. Cell Cycle Res., 4, 413-21 (2003).
PubMed Abstract 12576328, also cited as Blood, 101/11,4589-97 (2003).
PubMed Abstract 12554671, also cited as EMBO J. 22/3, 713-23(2003).
PubMed Abstract 8384080, also cited as Cancer Res. 43/7, 1599-601 (1993).
Chemical Abstract DN 130:209605, also cited as WO 9911621.
Chemical Abstract DN 131:44827, also cited as WO 9929674.
Chemical Abstract DN 128:13243, also cited as Arch. der Pharm. (Weinheim, Germany) 330/7, 207-10 (1997).
Chemical Abstract DN 127:277898, also cited as Magnetic Reson. in Chem., 35/9, 653-55 (1997).
Chemical Abstract DN 124:75535, also cited as. Med. Chem., 39/1, 304-13 (1996).
Chemical Abstract DN 123:143653, also cited as CA 2132771 (1995).
Chemical Abstract DN 112:216860, also cited as Acta Poloniae Pharm. 46/2, 101-13 (1989).
Chemical Abstract DN 91:117865, also cited as Acta Poloniae Pharm. 35/5, 615-18 (19878).
Carter et al., Chemotherapy of Cancer, second edition, 362-65 (1981).
Chaplin et al, Chemical Abstract DN 114:77895, also cited as British J. Of Cancer, 62/4, 561-6(1990).
Chemical Abstract DN:4609659, also cited as U.S.P. 4609659, 1986.
Heinisch, et al., “Synthesis of N-aryl-N'-heteroaryl-substituted urea and thiourea derivatives and evaluation of their anticonvulsant activity” Archiv Der Pharmazie, VCH Verlagsgesellschaft MBH, Weinheim, DE, vol. 330, No. 7, Jul. 1, 1997, pp. 207-210.
Burgess Laurence Edward
Cook Adam Wade
Cowen Scott Douglas
Gaudino John Joseph
Kesicki Edward A.
Coleman Brenda L
Hostettler Danica
Icos Corporation
McGraw Elizabeth A.
Moore Susanna
LandOfFree
Urea or thiourea substituted 1,4-pyrazine compounds useful... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Urea or thiourea substituted 1,4-pyrazine compounds useful..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Urea or thiourea substituted 1,4-pyrazine compounds useful... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4115811